Abstract:In pursuit of enhancing the anti -resistance efficacy and solubility of our previously identified NNRTI 1 , a series of biphenyl-quinazoline derivatives were synthesized employing a structure -based drug design strategy. Noteworthy advancements in anti -resistance efficacy were discerned among some of these analogs, prominently exemplified by compound 7ag , which exhibited a remarkable 1.37 to 602.41-fold increase in potency against mutant strains (Y181C, L100I, Y188L, F227L + V106A, and K103N + Y181C) in comparison to compound 1 . Compound 7ag also demonstrated comparable anti -HIV activity against both WT HIV and K103N, albeit with a marginal reduction in activity against E138K. Of significance, this analog showed augmented selectivity index (SI > 5368) relative to compound 1 (SI > 37764), Nevirapine (SI > 158), Efavirenz (SI > 269), and Etravirine (SI > 1519). Moreover, it displayed a significant enhancement in water solubility, surpassing that of compound 1 , Etravirine, and Rilpivirine. To elucidate the underlying molecular mechanisms, molecular docking studies were undertaken to probe the critical interactions between 7ag and both WT and mutant strains of HIV -1 RT. These findings furnish invaluable insights driving further advancements in the development of DAPYs for HIV therapy.

Improving the Anti-Hiv-1 Activity and Solubility of Poorly Water-Soluble DAPYs by Heteroaromatic Replacement Strategy: from Naphthalene-Dapys to Quinoline-Dapys.

Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: from Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs

Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK

Synthesis and Biological Evaluation of CHX-DAPYs As HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Structure-guided Design of Novel Biphenyl-Quinazoline Derivatives As Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Improved Anti-Resistance, Selectivity, and Solubility

Optimization of the Antiviral Potency and Lipophilicity of Halogenated 2,6‐diarylpyridinamines As a Novel Class of HIV‐1 NNRTIS

Structure-based discovery of novel piperidine-biphenyl-DAPY derivatives as non-nucleoside reverse transcriptase inhibitors featuring improved potency, safety, and selectivity: From piperazine-biphenyl-DAPYs to piperidine-biphenyl-DAPYs

Chemical space exploration of novel naphthyl-carboxamide-diarylpyrimidine derivatives with potent anti-HIV-1 activity

Structural Modification of Diarylpyrimidine Derivatives As HIV-1 Reverse Transcriptase Inhibitors

Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses

Structural Modifications of Dapy Analogues with Potent Anti-Hiv-1 Activity

Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.

Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.

Structural Modifications of CH(OH)-DAPYs As New HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.

Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.

Follow On-Based Optimization of the Biphenyl-Dapys As HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors Against the Wild-Type and Mutant Strains.

Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.

Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs

Fragment Hopping-Based Discovery of Novel Sulfinylacetamide-Diarylpyrimidines (dapys) As HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors

Design, Synthesis, and Sar of Naphthyl-Substituted Diarylpyrimidines As Non-Nucleoside Inhibitors of Hiv-1 Reverse Transcriptase

Hybrids of delavirdine and piperdin-4-yl-aminopyrimidines (DPAPYs) as potent HIV-1 NNRTIs: Design, synthesis and biological activities